Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang. Coronavirus disease-2019 (COVID-19) memiliki spektrum penyakit yang sangat luas dari gejala ringan sampai berat, hingga kematian. Reaksi inflamasi berat akibat dari COVID-19 ini menimbulkan gangguan hemostasis yang disebut dengan COVID-19 associated coagulopathy. Penelitian ini bertujuan untuk menilai profil koagulasi pada pasien dalam pemantauan (PDP) ataupun terkonfirmasi COVID-19 serta hubungannya terhadap mortalitas 30-hari pasien. Metode. Studi ini merupakan studi kohort retrospektif di RS Cipto Mangunkusumo (RSCM) selama Maret 2020 hingga Juni 2020. Sebanyak 106 subjek yang sesuai kriteria inklusi dianalisis dari data rekam medis. Dilakukan pengambilan data berupa data demografik, klinis atau hemodinamik pasien, profil koagulasi saat subjek ditentukan sebagai PDP atau terkonfirmasi COVID-19, pemberian terapi tromboprofilaksis heparin, dan status mortalitas 30 hari setelah admisi. Perhitungan statistik dilakukan dengan menggunakan Statistical Package of Social Science (SPSS) versi 24.0. Profil koagulasi subjek penyintas 30 hari dibandingkan dengan subjek yang mengalami mortalitas. Variabel profil koagulasi yang bermakna kemudian dianalisis dengan analisis bivariat dan regresi logistik multivariat. Hasil. Pada kelompok yang mengalami mortalitas 30-hari ditemukan adanya peningkatan jumlah leukosit (p: 0,022), penurunan kadar trombosit (p: 0,016), dan waktu protrombin (PT) dan waktu activated partial thromboplastin time (APTT) yang lebih panjang (p: 0,002 dan p: 0,018) dibandingkan pada kelompok penyintas 30-hari. Tidak ditemukan perbedaan fibrinogen dan d-Dimer yang bermakna secara statistik. PT merupakan suatu profil koagulasi tunggal yang dapat digunakan sebagai prediktor mortalitas 30-hari dengan odds ratio (95% CI) sebesar 1,407 (1,072 – 1,846), nilai p: 0,014.Simpulan. Terdapat hubungan antara faktor koagulasi pasien COVID-19 dengan mortalitas 30 hari di RSCM, khususnya PT yang dapat digunakan sebagai prediktor mortalitas 30-hari.

---

Background. Coronavirus disease-2019 (COVID-19) has a very broad spectrum of disease from mild to severe symptoms, to death. The severe inflammatory reaction as a result of COVID-19 infection causes a hemostasis disorder called COVID-19 associated coagulopathy. This study aims to assess the coagulation profile of patients under monitoring (PDP) or confirmed COVID-19 and its relationship with 30-day mortality.

Method. This retrospective cohort study was conducted at RS Cipto Mangunkusumo (RSCM) from March 2020 to June 2020. A total of 106 subjects who met the inclusion criteria were analyzed from medical record data. Data were collected in the form of patient demographic, clinical or hemodynamic data, coagulation profile when the subject was determined as PDP or confirmed as COVID-19, administration of heparin thromboprophylaxis therapy, and mortality status 30 days after admission. Statistical calculations were performed using the Statistical Package of Social Science (SPSS) version 24.0. We compared the coagulation profiles of the survivor group in contrast to the non-survivor group. Significant coagulation profile variables were analyzed using bivariate analysis and multivariate logistic regression.

Results. There was elevated number of leukocytes (p: 0.022), reduced platelet levels (p: 0.016), and longer prothrombin time (PT) as well as activated partial thromboplastin time (APTT) (p: 0.002 and p: 0.018, consecutively) in non-survivor group. There were no statistical differences in fibrinogen and d-Dimer levels in both groups. Additionally, PT is a single coagulation profile which predicted 30- day mortality with an odds ratio (95% CI) of 1.407 (1.072 - 1.846), and p value: 0.014.

Conclusion. This present study shows abnormal coagulation results are associated with 30-day mortality in COVID-19 patients at RSCM. Prolonged PT was an independent predictor for 30-day mortality in COVID-19 patients."

"Latar belakang. Coronavirus disease-2019 (COVID-19) memiliki spektrum penyakit yang sangat luas dari gejala ringan sampai berat, hingga kematian. Reaksi inflamasi berat akibat dari COVID-19 ini menimbulkan gangguan hemostasis yang disebut dengan COVID-19 associated coagulopathy. Penelitian ini bertujuan untuk menilai profil koagulasi pada pasien dalam pemantauan (PDP) ataupun terkonfirmasi COVID-19 serta hubungannya terhadap mortalitas 30-hari pasien.Metode. Studi ini merupakan studi kohort retrospektif di RS Cipto Mangunkusumo (RSCM) selama Maret 2020 hingga Juni 2020. Sebanyak 106 subjek yang sesuai kriteria inklusi dianalisis dari data rekam medis. Dilakukan pengambilan data berupa data demografik, klinis atau hemodinamik pasien, profil koagulasi saat subjek ditentukan sebagai PDP atau terkonfirmasi COVID-19, pemberian terapi tromboprofilaksis heparin, dan status mortalitas 30 hari setelah admisi. Perhitungan statistik dilakukan dengan menggunakan Statistical Package of Social Science (SPSS) versi 24.0. Profil koagulasi subjek penyintas 30 hari dibandingkan dengan subjek yang mengalami mortalitas. Variabel profil koagulasi yang bermakna kemudian dianalisis dengan analisis bivariat dan regresi logistik multivariat.Hasil. Pada kelompok yang mengalami mortalitas 30-hari ditemukan adanya peningkatan jumlah leukosit (p: 0,022), penurunan kadar trombosit (p: 0,016), dan waktu protrombin (PT) dan waktu activated partial thromboplastin time (APTT) yang lebih panjang (p: 0,002 dan p: 0,018) dibandingkan pada kelompok penyintas 30-hari. Tidak ditemukan perbedaan fibrinogen dan d-Dimer yang bermakna secara statistik. PT merupakan suatu profil koagulasi tunggal yang dapat digunakan sebagai prediktor mortalitas 30-hari dengan odds ratio (95% CI) sebesar 1,407 (1,072 – 1,846), nilai p: 0,014.Simpulan. Terdapat hubungan antara faktor koagulasi pasien COVID-19 dengan mortalitas 30 hari di RSCM, khususnya PT yang dapat digunakan sebagai prediktor mortalitas 30-hari.

---

.Background. Coronavirus disease-2019 (COVID-19) has a very broad spectrum of disease from mild to severe symptoms, to death. The severe inflammatory reaction as a result of COVID-19 infection causes a hemostasis disorder called COVID-19 associated coagulopathy. This study aims to assess the coagulation profile of patients under monitoring (PDP) or confirmed COVID-19 and its relationship with 30-day mortality.

Method. This retrospective cohort study was conducted at RS Cipto Mangunkusumo (RSCM) from March 2020 to June 2020. A total of 106 subjects who met the inclusion criteria were analyzed from medical record data. Data were collected in the form of patient demographic, clinical or hemodynamic data, coagulation profile when the subject was determined as PDP or confirmed as COVID-19, administration of heparin thromboprophylaxis therapy, and mortality status 30 days after admission. Statistical calculations were performed using the Statistical Package of Social Science (SPSS) version 24.0. We compared the coagulation profiles of the survivor group in contrast to the non-survivor group. Significant coagulation profile variables were analyzed using bivariate analysis and multivariate logistic regression.

Results. There was elevated number of leukocytes (p: 0.022), reduced platelet levels (p: 0.016), and longer prothrombin time (PT) as well as activated partial thromboplastin time (APTT) (p: 0.002 and p: 0.018, consecutively) in non-survivor group. There were no statistical differences in fibrinogen and d-Dimer levels in both groups. Additionally, PT is a single coagulation profile which predicted 30-day mortality with an odds ratio (95% CI) of 1.407 (1.072 - 1.846), and p value: 0.014.

Conclusion. This present study shows abnormal coagulation results are associated with 30-day mortality in COVID-19 patients at RSCM. Prolonged PT was an independent predictor for 30-day mortality in COVID-19 patients"

"Latar Belakang: COVID-19 menyebabkan penyakit kritis dan kematian dengan manifestasi utama sindrom pernafasan akut. Prediktor kematian pada kasus COVID-19, seperti IL-6 berperan dalam mengatur respon imun dan inflamasi. Pada kasus berat, peningkatan IL-6 dapat menyebabkan sepsis dan kegagalan multi-organ. CRP juga berkontribusi signifikan terhadap peradangan. Keparahan derajat COVID-19 dipengaruhi oleh komorbiditas seperti penyakit kardiovaskular, diabetes melitus tipe II, dan hipertensi. Tocilizumab, penghambat reseptor IL-6 merupakan terapi baru untuk pasien COVID-19 berat dan kritis. Penelitian ini menilai mortalitas pasien COVID-19 berat yang diberikan dan tidak diberikan terapi tocilizumab setelah dikontrol oleh variabel perancu. Tujuan: Menganalisis pengaruh terapi tocilizumab terhadap kematian pada pasien COVID-19 berat. Metode: Desain penelitian kohort retrospektif, menggunakan data rekam medis pasien COVID-19 di ICU RSCM selama dua tahun. Data dianalisis menggunakan SPSS. Hasil: Total 80 subjek, 52 pasien meninggal dan 28 pasien hidup. Mayoritas pasien memiliki CRP tinggi, IL-6 meningkat, serta tidak memiliki komorbid hipertensi, diabetes mellitus tipe II, dan penyakit kardiovaskular. Analisis statistik menunjukkan tidak ada hubungan yang signifikan antara pemberian terapi tocilizumab dan kematian, serta tidak terdapat perancu dalam penelitian ini. Kesimpulan: Pemberian terapi tocilizumab tidak memperbaiki kejadian mortalitas pada pasien COVID-19 berat.

---

Background: COVID-19 causes critical illness and death with the main manifestation of acute respiratory syndrome. Predictors of death in COVID-19 cases, such as IL-6, play a role in regulating the immune response and inflammation. In severe cases, increased IL-6 can cause sepsis and multi-organ failure. CRP also contributes significantly to inflammation. The severity of COVID-19 is influenced by comorbidities such as cardiovascular disease, type II diabetes mellitus, and hypertension. Tocilizumab, an IL-6 receptor inhibitor, is a new therapy for severe and critical COVID-19 patients. This study assessed the mortality of severe COVID-19 patients who were and were not given tocilizumab therapy after controlling for confounding variables. Objective: To analyze the effect of tocilizumab therapy on mortality in severe COVID-19 patients. Methods: Retrospective cohort study design, using medical record data of COVID-19 patients in the ICU RSCM for two years. Data were analyzed using SPSS. Results: A total of 80 subjects, 52 patients died and 28 patients survived. The majority of patients had high CRP, increased IL-6, and did not have comorbid hypertension, type II diabetes mellitus, and cardiovascular disease. Statistical analysis showed no significant association between tocilizumab therapy and mortality, and there were no confounders in this study. Conclusion: Administration of tocilizumab therapy does not reducing mortality rates in severe COVID-19 patients."

"Latar BelakangCOVID-19 adalah sebuah infeksi virus yang memiliki angka mortalitas yang sangat tinggi dalam periode waktu yang sangat sempit. Infeksi COVID-19 akan menyebabkan inflamasi di jaringan paru tubuh yang dapat diukur dengan serum D-dimer. Keparahan gejala dari infeksi COVID-19 dapat dilihat dalam gejala klinis dan keterlibatan segmen paru pada gambaran CT-Scan. Penelitian ini bertujuan untuk mengetahui hubungan antara level D-dimer dengan keparahan klinis pasien COVID-19 serta dengan keterlibatan lobus paru pada gambaran CT-Scan pasien COVID-19MetodePenelitian ini menggunakan metode potong lintang retrospektif dengan uji korelasi gamma untuk melihat hubungan antara level d-dimer dengan keparahan klinis dan keparahan gambaran CT-Scan pada pasien COVID-19. Penelitian ini menggunakan data sekunder dari penelitian “Implementasi Pencitraan Diagnostik Foto Toraks dan CT- Scan Toraks Coronavirus Disease 2019 (COVID-19) Menggunakan Artificial Intelligence” oleh Kamelia T, dkk. di tiga rumah sakit (Rumah Sakit Bunda Menteng, Rumah Sakit Bunda Depok, dan Rumah Sakit dr. Cipto Mangunkusumo) dalam periode 2020-2024, dimana terdapat 50 subjek yang melakukan pemeriksaan laboratorium (D- dimer) dan pemeriksaan CT-Scan.HasilDidapatkan 50 subjek dimana terdapat 25 (50%) subjek yang mengalami peningkatan level D-dimer dan 25 (50%) subjek dengan level D-dimer normal. Uji korelasi antara level D-dimer dengan keparahan klinis memiliki nilai P <0,001 dengan koefiesien korelasi sebesar 0,806. Uji korelasi antara level D-dimer dengan keparahan CT-Scan memiliki nilai P 0,012 dengan koefisien korelasi sebesar 0,528. Koefisien korelasi yang dianggap bermakna pada penelitian ini adalah 0,4.KesimpulanLevel D-dimer memiliki korelasi sangat kuat dengan keparahan klinis serta korelasi sedang dengan keparahan CT-Scan, sehingga dapat menjadi biomarker potensial untuk menentukan tingkat keparahan gejala klinis pasien dan keparahan gambaran CT-Scan thoraks pasien COVID-19.

---

Introduction

COVID-19 is a viral infection associated with a high mortality rate within a relatively short period. The infection triggers inflammation in lung tissues, which can be measured using serum D-dimer levels. The severity of COVID-19 symptoms can be assessed through clinical manifestations and the extent of pulmonary segment involvement observed on CT-Scan imaging. This study aims to determine the correlation between D- dimer levels and the clinical severity of COVID-19, as well as the involvement of pulmonary lobes on CT-Scan images of COVID-19 patients.

Method

This study employed a retrospective cross-sectional method with a gamma correlation test to examine the relationship between D-dimer levels, clinical severity, and CT-Scan severity in COVID-19 patients. This study utilized secondary data from the research “Implementation of Diagnostic Imaging of Chest X-rays and CT-Scans for Coronavirus Disease 2019 (COVID-19) Using Artificial Intelligence” by Kamelia T, et al., conducted at three hospitals (Bunda Menteng Hospital, Bunda Depok Hospital, and Dr. Cipto Mangunkusumo Hospital) from 2020 to 2024, involving 50 subjects who underwent laboratory (D-dimer) and CT-Scan examinations.

Results

A total of 50 subjects were included, with 25 (50%) showing elevated D-dimer levels and 25 (50%) with normal D-dimer levels. The correlation test between D-dimer levels and clinical severity showed a p-value <0.001 with a correlation coefficient of 0.806. The correlation test between D-dimer levels and CT-Scan severity yielded a p-value of 0.012 with a correlation coefficient of 0.528. A correlation coefficient of 0.4 or higher was considered significant in this study.

Conclusion

D-dimer levels can serve as a potential biomarker for determining the severity of clinical symptoms and the severity of thoracic CT-Scan findings in COVID-19 patients."

"Latar BelakangPandemi COVID-19, yang disebabkan oleh SARS-CoV-2, berdampak global, termasuk di Indonesia, dengan komplikasi utama seperti trombosis terkait peningkatan kadar D- dimer, biomarker pembekuan darah. Kadar D-dimer yang tinggi dikaitkan dengan prognosis buruk, seperti risiko trombosis, lama rawat inap yang lebih lama, dan kematian. Penelitian ini bertujuan mengeksplorasi hubungan antara kadar D-dimer, tingkat keparahan penyakit, dan lama rawat pasien COVID-19 di RSUP Persahabatan.MetodePenelitian ini bersifat observasional-analitis dengan desain potong lintang pada pasien COVID-19 derajat sedang, berat, dan kritis di RSUP Persahabatan, Jakarta, selama Januari–Desember 2021. Data dikumpulkan dari rekam medis dan dianalisis dengan metode consecutive sampling, melibatkan 57 sampel. Penelitian mencakup pengukuran kadar D-dimer, tingkat keparahan penyakit, dan lama rawat inap. Analisis data dilakukan menggunakan SPSS 25.0 dengan uji univariat dan bivariat, termasuk uji Chi-square atau Fisher’s exact untuk memeriksa hubungan antarvariabel.HasilHasil penelitian ini menunjukkan bahwa tidak ada hubungan signifikan antara kadar D- dimer awal dengan tingkat keparahan COVID-19 (p=0,364), meskipun subjek dengan kadar D-dimer ≥500 ng/mL lebih banyak mengalami kondisi sedang dan berat. Di sisi lain, kadar D-dimer yang lebih tinggi (≥500 ng/mL) berhubungan dengan durasi rawat inap yang lebih lama (≥14 hari) dengan p=0,044, menunjukkan perbedaan signifikan antara kadar D-dimer dan lama rawat inap pasien COVID-19.KesimpulanPenelitian ini menunjukkan bahwa tidak ada hubungan signifikan antara kadar D-dimer awal dengan tingkat keparahan COVID-19 (p=0,364), namun kadar D-dimer ≥500 ng/mL berhubungan dengan durasi rawat inap yang lebih lama (≥14 hari) (p=0,044).

---

Introduction

The COVID-19 pandemic, caused by SARS-CoV-2, has had a global impact, including in Indonesia, with major complications such as thrombosis associated with elevated D- dimer levels, a biomarker of blood coagulation. High D-dimer levels are linked to poor prognosis, including the risk of thrombosis, prolonged hospital stays, and mortality. This study aims to explore the relationship between D-dimer levels, disease severity, and length of hospitalization in COVID-19 patients at RSUP Persahabatan.

Method

This study is an observational-analytical research with a cross-sectional design conducted on COVID-19 patients with moderate, severe, and critical conditions at RSUP Persahabatan, Jakarta, from January to December 2021. Data were collected from medical records and analyzed using consecutive sampling methods, involving 57 samples. The study includes measurements of D-dimer levels, disease severity, and length of hospitalization. Data analysis was performed using SPSS 25.0 with univariate and bivariate tests, including Chi-square or Fisher’s exact tests to examine the relationships between variables.

Results

The results of this study indicate that there is no significant relationship between initial D-dimer levels and the severity of COVID-19 (p=0.364), although subjects with D-dimer levels ≥500 ng/mL were more likely to experience moderate and severe conditions. On the other hand, higher D-dimer levels (≥500 ng/mL) are associated with longer hospital stays (≥14 days) with a p-value of 0.044, indicating a significant difference between D- dimer levels and the duration of hospitalization in COVID-19 patients.

Conclusion

This study shows that there is no significant relationship between initial D-dimer levels and COVID-19 severity (p=0.364), but D-dimer levels ≥500 ng/mL are associated with longer hospital stays (≥14 days) (p=0.044)."

"Latar belakang: COVID-19 telah menyebabkan pandemi dengan angka mortalitas yang signifikan. Indonesia merupakan salah satu negara dengan angka kematian tertinggi akibat COVID-19. Beberapa faktor risiko yang menyebabkan kematian pada pasien COVID-19 memiliki kesamaan dengan faktor risiko pada infeksi SARS-CoV dan MERS- CoV, seperti usia, komorbiditas, kadar neutrofil dan limfosit, d-dimer, serta jumlah lobus paru yang terlibat berdasarkan temuan rontgen toraks.Tujuan: Penelitian ini bertujuan untuk mengidentifikasi proporsi kematian dan faktor- faktor yang memengaruhi mortalitas pasien COVID-19 dalam perawatan ≤ 14 hari, dengan pendekatan komprehensif yang mencakup anamnesis, pemeriksaan fisik dasar, dan pemeriksaan penunjang sederhana yaitu pemeriksaan laboratorium darah dan rontgen toraks.Metode: Penelitian ini menggunakan desain retrospektif observasional dengan menganalisis rekam medis pasien COVID-19 yang dirawat di RSUPN Cipto Mangunkusumo dari Januari 2021 hingga Januari 2024. Data dianalisis menggunakan program STATA versi 17.0 melalui metode analisis univariat, bivariat, dan regresi logistik.Hasil: Sebanyak 142 subjek direkrut dan dianalisis, dengan angka mortalitas selama perawatan mencapai 29,57%. Mayoritas pasien berjenis kelamin laki-laki (58,5%) dan berusia >60 tahun (52,8%), serta sebagian besar mengalami ketergantungan total (85,7%). Sebagian besar subjek memiliki status nutrisi obesitas (43%). Komorbiditas terbanyak adalah diabetes melitus (42,3%), hipertensi (39,4%), dan gangguan ginjal kronis (37,3%), sedangkan mortalitas tertinggi ditemukan pada pasien dengan gangguan ginjal kronis (34%), penyakit jantung koroner (33,3%), dan stroke (29,2%). Faktor signifikan yang memengaruhi mortalitas dalam ≤14 hari meliputi usia (OR 3,17, p = 0,016), D-dimer (OR 3,07, p = 0,015), CRP (OR 5,16, p < 0,001), dan SpO2 (OR 8,64, p < 0,001).Kesimpulan: Proporsi mortalitas pasien COVID-19 dalam perawatan ≤ 14 hari adalah 29,57%. Mortalitas sebagian besar terjadi pada pasien berusia ≥60 tahun dengan ketergantungan total. Faktor usia, D-dimer, CRP, dan SpO2 terbukti sebagai faktor yang memengaruhi mortalitas pasien COVID-19 selama perawatan.

---

Background: COVID-19 has caused a pandemic with a significant mortality rate. Indonesia is among the countries with the highest death toll from COVID-19. Several risk factors contributing to mortality in COVID-19 patients are similar to those observed in SARS-CoV and MERS-CoV infections, such as age, comorbidities, neutrophil-to- lymphocyte ratio, D-dimer levels, and the number of lung lobes affected as identified through chest X-ray findings.

Aim: This study aims to identify the proportion of mortality and the factors influencing the mortality of COVID-19 patients within ≤ 14 days of care, using a comprehensive approach that includes medical history, basic physical examination, and simple supporting tests, namely blood laboratory tests and chest X-rays

Methods: This study employs a retrospective observational design by analyzing the medical records of COVID-19 patients treated at RSUPN Cipto Mangunkusumo from January 2021 to January 2024. The data were analyzed using STATA version 17.0 software through univariate, bivariate, and logistic regression analysis methods.

Results: A total of 142 subjects were recruited and analyzed, with a mortality rate of 29.57% during ≤14 days of treatment. Most patients were male (58.5%) and aged over 60 years (52.8%), with the majority experiencing total dependence (85.7%). Obesity was the predominant nutritional status among the subjects (43%). The most prevalent comorbidities included diabetes mellitus (42.3%), hypertension (39.4%), and chronic kidney disease (37.3%). The highest mortality rates were found in patients with chronic kidney disease (34%), coronary artery disease (33.3%), and stroke (29.2%). Significant factors affecting mortality within ≤14 days included age (OR 3.17, p = 0.016), D-dimer (OR 3.07, p = 0.015), CRP (OR 5.16, p < 0.001), and SpO2 (OR 8.64, p < 0.001).

Conclusion: The mortality proportion of COVID-19 patients during ≤14 days of treatment is 29.57%. The majority of mortality occurred in patients over 60 years old with total dependence. Age, D-dimer, CRP, and SpO2 were found to be significant factors influencing mortality in COVID-19 patients during treatment."

"Latar Belakang: Penggunaan heparin inhalasi pada beberapa penelitian COVID-19memberikan hasil dalam perbaikan klinis pasien, baik dalam menurunkan lama rawat,perbaikan oksigenasi paru, dan mortalitas. Dosis harian total heparin inhalasi yangbervariasi terutama bila diberikan bersamaan dengan antikoagulan sistemik, memilikiresiko komplikasi perdarahan yang memerlukan kajian terhadap keefektifan dankeamanannya.Tujuan: Meneliti keefektifan dan keamanan inhalasi heparin dosis 150,000 IU/haridengan dosis 100.000 IU/hari dinilai dari AaDO2, aPTT dan d-Dimer dalam 7 haripengamatan pada pasien ICU COVID-19.Metode: Penelitian ini merupakan penelitian observasional dengan studi kohortretrospektif menggunakan data sekunder rekam medis pasien ICU COVID-19 bulanSeptember 2020 – September 2021. Terdapat 300 sampel menggunakan consecutivesampling. Pasien dikelompokkan menjadi kelompok heparin dosis 150.000 IU/hari dan100.000 IU/hari. Pencatatan dilakukan dalam 7 hari pengamatan. Uji Statistikmenggunakan uji Mann Whitney untuk menilai tingkat keparahan, Uji Wilcoxon rank testuntuk melihat perbedaan variabel dependen hari pertama dengan hari ketujuh padamasing-masing dosis.Hasil: Heparin inhalasi baik dosis 150.000 IU/hari dan 100.000 IU /hari bermaknamenurunkan AaDO2 pada 7 hari pengamatan (p 0.001). Nilai aPTT tidak memanjangpada kedua kelompok, dan kedua dosis heparin sama- sama menurunkan nilai d-Dimerpada 7 hari pengamatan (p 0.001).Simpulan: Heparin Inhalasi dosis 150.000 IU/hari sama efektif dinilai dari AaDO2, dansama amannya terhadap aPTT dan d-Dimer dibandingkan heparin inhalasi dosis 100.000IU/hari.

---

Rationale: The use of inhaled heparin in several COVID-19 studies has resulted in

clinical improvements in patients, both in reducing length of treatment, improving

pulmonary oxygenation, and reducing mortality. The varying total daily dose of inhaled

heparin, especially when given together with systemic anticoagulants, poses a risk of

bleeding complications that require review of its effectiveness and safety.

Objective: To analyze effectiveness and safety of heparin inhalation dosage 150,000

IU/day compare to 100,000 IU/day assessed from AaDO2, aPTT and d-Dimer from 7

days observation in ICU COVID-19 patients with invasive and non-invasive ventilator

patterns.

Methods: An observational cohort retrospective study used secondary data from medical

records ICU COVID-19 patients with invasive and noninvasive ventilator patterns from

September 2020 – September 2021. There were 300 samples using consecutive sampling.

Patients divided into 2 groups, one received dosage 150,000 IU / day heparin inhalation,

the other received heparin inhalation dosage 100,000 IU / day. Recording of the research

from medical records is carried out at 7 days of ICU treatment. Statistical tests were

carried out using Mann Whitney to assess severity, Wilcoxon rank test to see the

difference in dependent variables day 1 and day 7 to dose.

Measurements and Main Results: Heparin inhalation at dose of 150,000 IU/day and

100,000 IU/day both significantly decreased AaDO2 at 7 days of observation (p 0.001).

The aPTT on both groups at 7 days of observation are within normal limits. Both doses

of heparin inhalation decreased d-dimer at 7 days of observation (p 0.001).

Conclusion: Inhaled heparin doses of 150,000 IU/day as effective and as safe as inhaled

heparin doses of 100,000 IU/day."

"COVID-19 atau coronavirus disease 2019 adalah penyakit menular yang memengaruhi sistem organ, terutama sistem pernapasan dan disebabkan oleh virus SARS-CoV-2. Individu yang terinfeksi COVID-19 memiliki tingkat keparahan yang berbeda. Salah satu faktor yang berasosiasi terhadap tingkat keparahan pasien COVID-19 adalah usia. Tingkat keparahan yang tinggi pada kondisi seseorang cenderung mempengaruhi banyaknya treatment yang dibutuhkan, hingga akhirnya juga mempengaruhi waktu yang dibutuhkan seseorang tersebut untuk sembuh. Penelitian ini berfokus pada faktor usia, dimana faktor tersebut diduga menyebabkan perbedaan karakteristik tertentu dari pasien dan durasi rawat yang dibutuhkan oleh pasien COVID-19. Tujuan dari penelitian ini adalah untuk menganalisis perbandingan karakteristik pasien COVID-19 berdasarkan kelompok usia, dan mengidentifikasi bagaimana kaitan usia terhadap durasi rawat pasien COVID-19 hingga mengalami kematian, perbaikan kondisi COVID, dan rawat jalan. Analisis perbandingan karakteristik pasien COVID-19 berdasarkan kelompok usia dilakukan dengan menerapkan metode exploratory data analysis (EDA). Selanjutnya metode EDA dan regression tree diterapkan untuk mengetahui bagaimana kaitan usia terhadap durasi rawat pasien COVID-19 hingga mengalami kematian, perbaikan kondisi, dan rawat jalan. Hasil yang diperoleh pada penelitian ini adalah terdapat kecenderungan perbedaan pada pasien COVID-19 berdasarkan kelompok usia jika dilihat berdasarkan faktor jenis kelamin, durasi rawat, status akhir, gejala, komorbid, komplikasi, dan pengukuran laboratorium darah. Selain itu, usia merupakan pertimbangan utama dalam memperkirakan durasi rawat pasien COVID-19 dengan faktor lainnya adalah hipertensi, klorida, HPR, PWR, MLR dan gejala demam.

---

COVID-19 or coronavirus disease 2019 is an infectious disease that affects the organ systems, especially the respiratory system and is caused by the SARS-CoV-2 virus. Individuals infected with COVID-19 have different levels of severity. One of the factors associated with the severity of COVID-19 patients is age. The severity level of a person tends to affect the number of treatments needed, and therefore will affect the time it takes for the person to recover. This study focuses on age, where this factor is suspected to cause differences in certain characteristics of COVID-19 patients and length of hospital stay required by COVID-19 patients. The purpose of this study is to analyse the characteristics comparison of COVID-19 patients by age group, and to identify on how age affects the length of hospital stay for COVID-19 patients to death, improved conditions, or outpatient care. Comparative analysis of the characteristics of COVID-19 patients by age group is done using exploratory data analysis (EDA). Furthermore, EDA and regression tree are used to find out how age is related to the length of hospital stay for COVID-19 patients to death, improved COVID conditions, or outpatient care. The results show that there was tendency of differences in gender, length of hospital stay, clinical outcome, symptoms, comorbidities, complications, and blood laboratory measurements in COVID-19 patients based on age group. In addition, age is a major consideration in estimating the length of hospital stay for COVID-19 patients with other factors such as hypertension, chloride, HPR, PWR, MLR and fever."

"Latar BelakangN-asetilsistein (NAC) merupakan kandidat potensial untuk strategi drug repurposing dalam menangani pandemi COVID-19, terutama untuk menurunkan progresi COVID-19 derajat berat yang dapat diprediksi oleh rasio neutrofil-limfosit (RNL). Namun, belum banyak studi yang meneliti hubungan NAC dengan RNL. Oleh karena itu, penelitian ini bertujuan untuk menilai hubungan pemberian NAC dengan RNL pasien COVID-19 derajat berat di RSUP Persahabatan.MetodePenelitian potong lintang dilakukan melalui rekam medis 60 pasien COVID-19 derajat berat di RSUP Persahabatan (mendapat NAC: 30; tidak mendapat NAC: 30). Studi ini meninjau karakteristik subjek penelitian berdasarkan usia, jenis kelamin, komorbiditas, dan riwayat pengobatan lain. Fokus penelitian ini adalah parameter RNL sebelum dan setelah perawatan. Analisis dilanjutkan dengan menilai hubungan pemberian NAC terhadap RNL.HasilSecara keseluruhan, terdapat 60 subjek yang mayoritas terdiri atas laki-laki (53,3%) dengan median usia 54 (23 – 69). Tidak ada perbedaan sebaran jenis kelamin, usia, komorbiditas, dan riwayat pengobatan lain antara kedua kelompok yang bermakna secara statistika. RNL kelompok yang mendapat NAC lebih rendah daripada kelompok yang tidak mendapat, baik sebelum perawatan (6,21 [2,21 – 33,32] vs 6,92 [2,25 – 36,15]) maupun setelah perawatan (5,14 [0,99 – 17,16] vs 5,74 [1,88 – 21,95]), tetapi perbedaan tersebut tidak signifikan secara statistika (p = 0,941; p = 0,451, masing-masing). Pemberian NAC tidak mempengaruhi penurunan RNL secara bermakna (p = 0,060). Adapun perbedaan median perubahan RNL antara dua kelompok tidak ditemukan bermakna (p = 0,460).KesimpulanNAC tidak signifikan secara statistik dalam menurunkan RNL pasien COVID-19 derajat berat.

---

Introduction

N-acetylcysteine (NAC) is a potential candidate for drug repurposing strategies in dealing with the COVID-19 pandemic, especially in reducing the development of severe COVID- 19 which can be predicted by the neutrophil-lymphocyte ratio (NLR). However, due to limited research of NAC’s effect on NLR, this study aims to assess their relationship in severe COVID-19 patients at Persahabatan Central General Hospital.

Method

A cross-sectional study from medical records of 60 severe COVID-19 patients at Persahabatan Central General Hospital (received NAC: 30; not received NAC: 30) reviewed the characteristics of the subjects based on age, gender, comorbidities, and other treatment history. This study focused on NLR before and after treatment, assessing the relationship between NAC administration and NLR.

Results

Most of the overall subjects were male (53.3%) with a median age of 54 (23–69). There was no statistically significant difference in the distribution of gender, age, comorbidities, and other treatment history between two groups. Group that received NAC had lower NLR than group that didn’t, both before treatment (6.21 [2.21–33.32] vs 6.92 [2.25– 36.15]) and after treatment (5.14 [0.99–17.16] vs 5.74 [1.88–21.95]), but the difference was not statistically significant (p = 0.941; p = 0.451, respectively). NAC administration did not significantly decrease NLR (p = 0.600). The difference in median changes in NLR between two groups was also not found to be significant (p = 0.460).

Conclusion

NAC did not statistically significant in reducing NLR in severe COVID-19 patients."

"Latar Belakang: Pandemi COVID-19 telah menjadi tantangan besar bagi dunia kesehatan. Tenaga kesehatan merupakan populasi yang sangat rentan tertular dikarenakan tingginya intensitas dan frekuensi pajanan SARS-CoV-2. Risiko penularan meningkat apabila tenaga medis melakukan tindakan yang memicu aerosilisasi, salah satunya adalah intubasi endotrakeal karena tingginya viral load pada saluran napas. Sebanyak 3,2% pasien COVID-19 memerlukan tindakan intubasi endotrakeal dan ventilasi mekanis. Intubasi endotrakeal yang efektif pada pasien COVID-19 penting dilakukan untuk menurunkan mortalitas dan risiko penularan. Penelitian ini bertujuan intuk mengetahui faktor-faktor yang memengaruhi efektivitas intubasi endotrakeal pada pasien terkonfirmasi COVID- 19 di RSUP Persahabatan.Metode: Penelitian ini merupakan penelitian observasional yang menggunakan desain potong lintang yang dilakukan di IGD, ICU Rasmin Rasjid dan ICU PINERE RSUP Persahabatan pada bulan Juni 2021 – Juni 2022. Subjek peneltian ini adalah pasien terkonfirmasi COVID-19 yang dilakukan tindakan intubasi endotrakeal yang memenuhi kriteria inklusi dan eksklusi. Tindakan intubasi endotrakeal dinilai dari observasi rekaman CCTV. Selanjutnya karakteristik subjek, karakteristik intubasi endotrakeal dan faktor-faktor yang memengaruhi intubasi endotrakeal dievaluasi.Hasil: Pada penelitian ini didapatkan 59 subjek penelitian. Proporsi intubasi endotrakeal efektif pada pasien COVID-19 sebesar 20,34%. Median lama waktu tindakan intubasi endotrakeal adalah 38 (19-189) detik. Sebanyak 32 (54,24%) tindakan intubasi endotrakeal dilakukan oleh spesialis anestesi dan 27 (45,76%) oleh PPDS Pulmonologi dan Kedokteran Respirasi. Hasil analisis bivariat didapatkan hasil bermakna secara statistik pada variabel penyakit kardiovaskular+DM (OR 0,24 (IK 95% 0,06-0,91), p=0,028) dan variabel operator (OR 0,07 (IK 95% 0,01-0,62), p=0,004). Hasil analisis multivariat menunjukkan hasil bermakna secara statistik hanya pada variabel operator (adjusted OR 0,06 (IK 95% 0,01-0,60), p=0,016).Kesimpulan: Terdapat hubungan penyakit kardiovaskular+DM dan operator terhadap intubasi endotrakeal efektif pada pasien COVID-19 di RSUP Persahabatan.

---

Background: The COVID-19 pandemic has become a major challenge for the healthcare system. Healthcare workers are vulnerable population of COVID-19 transmission due to high intensity and frequency of exposure to SARS-CoV-2. The risk of transmission increases in aerosolization procedure such as endotracheal intubation because of the high viral load in the airways. Approximately 3.2% of COVID-19 patients require endotracheal intubation and mechanical ventilation. Effective endotracheal intubation in COVID-19 patients is important parameter to reduce mortality and the risk of transmission to healthcare workers. This study aims to determine the factors that influence the effectiveness of endotracheal intubation in patients with COVID-19 in National Respiratory Center, Persahabatan Hospital.

Methods: This study is an observational study using a cross-sectional design which was carried out in the emergency department, ICU Rasmin Rasjid and ICU PINERE of National Respiratory Center, Persahabatan Hospital in June 2021 – June 2022. The subjects of this study were COVID-19 patients who underwent endotracheal intubation who met the criteria inclusion and exclusion. The endotracheal intubation procedure was assessed from the observation of CCTV recordings. The characteristics of the subject, the characteristics of endotracheal intubation and the factors that influence endotracheal intubation were evaluated.

Results: In this study, there were 59 subjects. The proportion of effective endotracheal intubation in COVID-19 patients was 20.34%. The median length of time for endotracheal intubation was 38 (19-189) seconds. Among the subjects, 32 (54.24%) endotracheal intubation were performed by anesthesiologists and 27 (45.76%) were performed by Pulmonology and Respiratory Medicine residents. The results of the bivariate analysis showed statistically significant results on the cardiovascular disease + DM comorbid (OR 0.24 (95% CI 0.06-0.91), p=0.028) and operator (OR 0.07 (95% CI 0.01-0.62), p=0.04). The results of the multivariate analysis showed statistically significant results only for operator (adjusted OR 0.06 (95% CI 0.01-0.60), p=0.016).

Conclusion: There is relationship of cardiovascular disease + DM comorbid and operator with effective endotracheal intubation in COVID-19 patients at National Respiratory Center, Persahabatan Hospital."